PTJ
EIKN

Paul Tudor Jones’s Eikon Therapeutics EIKN Stock Holding History

Paul Tudor Jones’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$196K Hold
15,000
– – ﹤0.01% 3339
2026
Q1 		$159K Buy
+15,000
New +$200K ﹤0.01% 3408

Other funds holding EIKN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Paul Tudor Jones's EIKN Position: Q2 2026 in Review

Paul Tudor Jones held its Eikon Therapeutics (EIKN) position steady in Q2 2026 at 15,000 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #3339.

Paul Tudor Jones first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • Paul Tudor Jones held 15,000 shares of Eikon Therapeutics worth $196K as of Q2 2026.
  • Paul Tudor Jones left its Eikon Therapeutics share count unchanged in Q2 2026.
  • Eikon Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3339 holding.
  • Paul Tudor Jones first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.